Citius Oncology annual operating income
2021
2022
2022
2023
2023
2024
2025
Citius Oncology Operating Income Growth & History (CTOR)
Citius Oncology's operating income was −$23.5M for fiscal 2025.
View full Citius Oncology company overviewCitius Oncology annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | −$23.5M | −$3.0M | — |
| 2024 | 2024-09-30 | −$20.6M | −$8.5M | — |
| 2023 · Dec 31 | 2023-12-31 | −$1.0M | −$874,955 | — |
| 2023 · Sep 30 | 2023-09-30 | −$12.1M | −$7.3M | — |
| 2022 | 2022-12-31 | −$138,115 | −$128,002 | — |
| 2022 | 2022-09-30 | −$4.9M | — | — |
| 2021 | 2021-12-31 | −$10,113 | — | — |
Citius Oncology quarterly operating income
Q1.23
Q2.23
Q4.23
Q4.23
Q1.24
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | −$8.7M | −$3.8M | — |
| Q2 2026 | 2026-03-31 | −$28.6M | −$21.1M | — |
| Q1 2026 | 2025-12-31 | −$5.3M | $1.1M | — |
| Q4 2025 | 2025-09-30 | −$4.7M | — | — |
| Q3 2025 | 2025-06-30 | −$4.9M | −$316,111 | — |
| Q2 2025 | 2025-03-31 | −$7.5M | −$7.2M | — |
| Q1 2025 | 2024-12-31 | −$6.4M | −$6.2M | — |
| Q2 2024 | 2024-06-30 | −$4.6M | −$4.4M | — |
| Q1 2024 | 2024-03-31 | −$268,429 | −$120,507 | — |
| Q4 2023 | 2023-12-31 | −$244,139 | — | — |
| Q4 2023 · Sep 30 | 2023-09-30 | −$421,455 | — | — |
| Q2 2023 | 2023-06-30 | −$199,554 | — | — |
| Q1 2023 | 2023-03-31 | −$147,922 | — | — |
Citius Oncology operating income trends
Between the periods ended 2021-12-31 and 2025-09-30, Citius Oncology's operating income decreased from −$10,113 to −$23.5M, a change of −$23.5M. The latest reported quarter, Q3 2026, shows −$8.7M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Citius Oncology source filings ↗Community posts
Citius Oncology’s wholesaler shipments rise sharply while institutional orders grow modestly
Citius Oncology ($CTOR) reported preliminary sales of 792 Lymphir units to US wholesalers for its fiscal fourth quarter of 2026, up 120% from 360 in the preceding quarter. Separately, prescribing centers ordered 950 vials from wholesalers, ...
